Search Results
Mar 04, 2026, 17:46 ET H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
Cinclus Pharma (STO: CINPHA), RaQualia Pharma (TYO: 4579), HK-inno.N (KOSDAQ: 195940), Braintree (Sebela Pharmaceuticals), RedHill BioPharma (NASDAQ: RDHL), Cumberland Pharmaceuticals (NASDAQ: CPIX), Phathom Pharmaceuticals (NASDAQ: PHAT), and others
More news about: DelveInsight Business Research, LLP
Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
PFE), Bold Therapeutics (NASDAQ: BOLD), Senhwa Biosciences, Virogin Biotech, Replimune (NASDAQ: REPL), Bayer (ETR: BAYN), RedHill Biopharma (NASDAQ: RDHL), Relay Therapeutics (NASDAQ: RLAY), Elevar Therapeutics, Eli Lilly (NYSE: LLY), Cogent Biosciences (Cogent Biosciences), Tanabe Pharma America (TYO:
More news about: DelveInsight Business Research, LLP
Feb 25, 2026, 07:00 ET Joint U.S. Commercialization of RedHill's Talicia® Commences
2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the full sales and operational launch of Talicia, under the
More news about: RedHill Biopharma Ltd.
Jan 05, 2026, 07:00 ET RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
TEL-AVIV, Israel and RALEIGH, N.C., Jan. 5, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced development progress for RHB-102 (Bekinda®) in multiple
More news about: RedHill Biopharma Ltd.
Dec 15, 2025, 07:00 ET RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 15, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced positive in vivo results, indicating that opaganib combined
More news about: RedHill Biopharma Ltd.
Dec 01, 2025, 07:00 ET RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26, 2025, it received confirmation from the Nasdaq
More news about: RedHill Biopharma Ltd.
Nov 04, 2025, 12:01 ET RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of
More news about: RedHill Biopharma Ltd.
Oct 22, 2025, 16:50 ET RedHill Biopharma Receives Nasdaq Staff Determination Notification
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on October 16, 2025, it received a Nasdaq Staff Determination
More news about: RedHill Biopharma
Oct 20, 2025, 09:05 ET CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment
More news about: Cumberland Pharmaceuticals Inc.
Oct 20, 2025, 09:00 ET RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
RALEIGH, N.C. and TEL AVIV, Israel, Oct. 20, 2025 /PRNewswire/ -- RedHill Biopharma Limited (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the signing of a strategic partnership with Cumberland Pharmaceuticals
More news about: RedHill Biopharma Ltd.
Oct 06, 2025, 08:00 ET RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the licensing of Talicia for new Middle East markets in a deal
More news about: RedHill Biopharma Ltd.
Sep 29, 2025, 07:00 ET RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that The New York Supreme Court has, on appeal, upheld its original
More news about: RedHill Biopharma Ltd.
Sep 05, 2025, 07:00 ET RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its first half of 2025 financial results and operational highlights
More news about: RedHill Biopharma Ltd.
Aug 20, 2025, 09:00 ET RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court has awarded RedHill approximately
More news about: RedHill Biopharma Ltd.
Aug 18, 2025, 09:00 ET RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received its first
More news about: RedHill Biopharma Ltd.
Jul 21, 2025, 09:00 ET RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
Israel, July 21, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received positive feedback from the U.S. Food and Drug
More news about: RedHill Biopharma Ltd.
Jul 01, 2025, 12:00 ET RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
N.C., July 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the initiation of patient recruitment into the Phase 2 study evaluating
More news about: RedHill Biopharma Ltd.
May 13, 2025, 07:00 ET RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it had won its attachment petition to the Court in South
More news about: RedHill Biopharma Ltd.
May 02, 2025, 07:00 ET RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its support of an independent
More news about: RedHill Biopharma Ltd.
Apr 28, 2025, 07:03 ET RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the China National Intellectual Property Administration
More news about: RedHill Biopharma Ltd.
Apr 17, 2025, 16:01 ET RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company received a written notification (the "Notification
More news about: RedHill Biopharma Ltd.
Apr 16, 2025, 07:00 ET RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
N.C., April 16, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the new
More news about: RedHill Biopharma Ltd.
Apr 10, 2025, 07:48 ET RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full-year 2024 financial results and operational highlights
More news about: RedHill Biopharma Ltd.